WeVote
Log In

Bill

Bill

HR 1632

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

119th Congress Introduced by Andy Harris and 1 co-sponsor

Promotes cross-state reciprocity to streamline access to lifesaving treatments, speeding approvals for patients, with mutual recognition among regulators and providers.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 1632

Summary: HR 1632 — Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Overview

  • Bill Number: HR 1632
  • Title: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
  • Status: Introduced in the House
  • Introduced: February 26, 2025
  • Primary Sponsor: Chip Roy
  • Cosponsor: Andy Harris
  • Short title (as introduced): “This Act may be cited as the Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025.”

Purpose and intent (as inferred from the title)

The bill’s name suggests an objective to promote reciprocity in order to streamline access to lifesaving treatments. While the exact statutory language is not provided in the version content available, the title indicates an emphasis on cross-jurisdictional or mutual-recognition mechanisms to speed up the use of critical medical treatments.

Provisions (as introduced)

  • The provided version content only includes the short title language and basic metadata. No substantive provisions or text outlining specific changes are included in the introduction.
  • The act is intended to be cited by its short title, per the introduced language.

Legislative actions and status

  • 2025-02-26: Introduced in the House.
  • 2025-02-26: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be determined by the Speaker, for consideration of provisions within each committee’s jurisdiction.
  • This is an early-stage bill: no floor passage, no committee reports, and no enacted provisions available in the introduced text.

Sponsors

  • Primary sponsor: Chip Roy
  • Cosponsor: Andy Harris

Potential impact and affected parties (high-level)

  • Patients: Could affect access pathways to lifesaving treatments across jurisdictions, potentially reducing delays caused by gaps in reciprocity or recognition.
  • Healthcare providers: May face new or streamlined processes for cross-jurisdictional authorization or use of treatments.
  • State and federal regulators: Could prompt harmonization or mutual-recognition mechanisms related to approval, eligibility, or dispensing of lifesaving treatments.
  • Payers/insurers: May need to adjust coverage or authorization criteria if treatment access is streamlined across jurisdictions.
  • Stakeholders should watch for the specific text to understand exact requirements, protections, funding (if any), privacy considerations, and implementation timelines.

Next steps and timeline

  • Monitor for committee hearings, amendments, and a potential floor vote.
  • Await release of the substantive legislative text to understand detailed provisions, funding, enforcement, and scope.

If you’d like, I can update this summary when the full text or committee reports become available, or compare HR 1632 to similar prior legislation.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.